Teachers Advisors LLC boosted its stake in Amgen (NASDAQ:AMGN) by 0.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,632,512 shares of the medical research company’s stock after acquiring an additional 1,842 shares during the period. Teachers Advisors LLC owned 0.23% of Amgen worth $283,894,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in the stock. South Texas Money Management Ltd. boosted its holdings in Amgen by 0.7% in the second quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock valued at $555,000 after acquiring an additional 22 shares in the last quarter. Glenview Trust Co boosted its holdings in Amgen by 0.4% in the second quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock valued at $1,057,000 after acquiring an additional 25 shares in the last quarter. Roberts Glore & Co. Inc. IL boosted its holdings in Amgen by 0.4% in the second quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock valued at $1,279,000 after acquiring an additional 27 shares in the last quarter. Salem Investment Counselors Inc. boosted its holdings in Amgen by 4.7% in the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 36 shares in the last quarter. Finally, Keel Point LLC boosted its holdings in Amgen by 1.2% in the second quarter. Keel Point LLC now owns 3,509 shares of the medical research company’s stock valued at $604,000 after acquiring an additional 43 shares in the last quarter. Institutional investors and hedge funds own 79.54% of the company’s stock.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $172.68, for a total value of $263,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 4,575 shares of company stock valued at $818,330. 0.19% of the stock is owned by insiders.
Shares of Amgen stock opened at $171.56 on Monday. The stock has a market capitalization of $114,648.57, a P/E ratio of 13.64, a PEG ratio of 2.10 and a beta of 1.36. Amgen has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.89 EPS. analysts expect that Amgen will post 13.28 earnings per share for the current fiscal year.
Amgen declared that its Board of Directors has authorized a share buyback program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
Several analysts recently weighed in on the stock. Mizuho lifted their price target on shares of Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a report on Monday, February 12th. Leerink Swann restated a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Morgan Stanley dropped their target price on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. TheStreet cut shares of Amgen from a “b-” rating to a “c+” rating in a report on Wednesday, April 11th. Finally, BMO Capital Markets boosted their target price on shares of Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $190.57.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.